Heterogeneity in risk of pelvic inflammatory diseases after chlamydia infection: A population-based study in Manitoba, Canada

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S549-S555

  Davies, Bethan ^a   Ward, Helen ^a   Leung, Stella ^c   Turner, Katy M E ^b   Garnett, Geoff P ^e   Blanchard, James F ^c   Yu, B Nancy ^c,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Manitoba Health   (Canada)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Chlamydia trachomatis; Cohort study; Cost effectiveness; Epidemiology; Mathematical models; Pelvic inflammatory disease; Retrospective study

Indexed keywords

ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; CANADA; CHILD; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COMPLICATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MICROBIOLOGY; PELVIC INFLAMMATORY DISEASE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; CHILD; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MANITOBA; PELVIC INFLAMMATORY DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; YOUNG ADULT;

EID: 84964313239     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu483     Document Type: Article

References (29)

1. European Centre for Disease Prevention and Control. Chlamydia control in Europe. Stockholm, Sweden: European Centre for Disease Prevention and Control, 2009.
2. Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? J Infect Dis 2010; 201(suppl 2): S156–67.
3. Adams EJ, Turner KM, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect 2007; 83:267–75.
4. Andersen B, Gundgaard J, Kretzschmar M, Olsen J, Welte R, Oster-Gaard L. Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis infections. Sex Transm Dis 2006; 33:407–15.
5. Low N, McCarthy A, Macleod J, et al. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess 2007; 11:iii–iv, ix-xii, 1–165.
6. Roberts TE, Robinson S, Barton PM, et al. Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project. Brit Med J 2007; 335:291–4A.
7. Townshend JRP, Turner HS. Analysing the effectiveness of chlamydia screening. J Oper Res Soc 2000; 51:812–24.
8. Tuite AR, Jayaraman GC, Allen VG, Fisman DN. Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada. Sex Transm Dis 2012; 39:260–7.
9. Welte R, Postma M, Leidl R, Kretzschmar M. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 2005; 32:474–83.
10. Davies B, Anderson SJ, Turner KM, Ward H. How robust are the natural history parameters used in chlamydia transmission dynamic models? a systematic review. Theor Biol Med Model 2014; 11:8.
11. Herzog SA, Heijne JC, Althaus CL, Low N. Describing the progression from Chlamydia trachomatis and Neisseria gonorrhoeae to pelvic inflammatory disease: systematic review of mathematical modeling studies. Sex Transm Dis 2012; 39:628–37.
12. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010; 201(suppl 2):S134–55.
13. Paavonen J. Chlamydia trachomatis in acute salpingitis. Am J Obstet Gynecol 1980; 138:957–9.
14. Stamm WE, Guinan ME, Johnson C, Starcher T, Holmes KK, McCormack WM. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med 1984; 310:545–9.
15. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (Prevention of Pelvic Infection) trial. BMJ 2010; 8:340.
16. Morre SA, van den Brule AJC, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002; 13:12–8.
17. Bakken IJ, Ghaderi S. Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study. BMC Infect Dis 2009; 9:130.
18. Low N, Egger M, Sterne JAC, et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women’s Cohort Study. Sex Transm Infect 2006; 82:212–8.
19. Hillis SD, Owens LM, Marchbanks PA, Amsterdam LF, Mac Kenzie WR. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997; 176:103–7.
20. Kimani J, Maclean IW, Bwayo JJ, et al. Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. J Infect Dis 1996; 173:1437–44.
21. Manitoba Centre for Health Policy. Population Health Research Data Repository. Available at: http://umanitoba.ca/faculties/medicine/units/community_health_sciences/departmental_units/mchp/resources/ repository/index.html. Accessed 28 November 2013.
22. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999; 149:916–24.
23. Moffatt DC, Yu BN, Yie W, Bernstein CN. Trends in utilization of diagnostic and therapeutic ERCP and cholecystectomy over the past 25 years: a population-based study. Gastrointest endosc 2014; 79:615–22.
24. Bakken IJ, Skjeldestad FE, Lydersen S, Nordbo SA. Births and ectopic pregnancies in a large cohort of women tested for Chlamydia trachomatis. Sex Transm Dis 2007; 34:739–43.
25. Roos LL, Nicol JP. A research registry: uses, development, and accuracy. J Clin Epidemiol 1999; 52:39–47.
26. Lix LM, Smith M, Azimaee M, et al. A systematic investigation of Manitoba’s provincial laboratory data. Winnipeg, MB: Manitoba Centre for Health Policy, December 2012.
27. Ratelle S, Yokoe D, Blejan C, et al. Predictive value of clinical diagnostic codes for the CDC case definition of pelvic inflammatory disease (PID): implications for surveillance. Sex Transm Dis 2003; 30:866–70.
28. Satterwhite CL, Yu O, Raebel MA, et al. Detection of pelvic inflammatory disease: development of an automated case-finding algorithm using administrative data. Infect Dis Obstet Gynecol 2011; 2011:428351.
29. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 2008; 35:119–23.